|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PIP4K2C |
Gene summary for PIP4K2C |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PIP4K2C | Gene ID | 79837 |
| Gene name | phosphatidylinositol-5-phosphate 4-kinase type 2 gamma | |
| Gene Alias | PIP5K2C | |
| Cytomap | 12q13.3 | |
| Gene Type | protein-coding | GO ID | GO:0000045 | UniProtAcc | B3KQV3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79837 | PIP4K2C | LZE4T | Human | Esophagus | ESCC | 1.37e-09 | 2.11e-01 | 0.0811 |
| 79837 | PIP4K2C | LZE7T | Human | Esophagus | ESCC | 4.08e-11 | 4.36e-01 | 0.0667 |
| 79837 | PIP4K2C | LZE8T | Human | Esophagus | ESCC | 1.42e-03 | 1.60e-01 | 0.067 |
| 79837 | PIP4K2C | LZE20T | Human | Esophagus | ESCC | 1.53e-03 | 1.68e-01 | 0.0662 |
| 79837 | PIP4K2C | LZE22T | Human | Esophagus | ESCC | 2.82e-03 | 2.68e-01 | 0.068 |
| 79837 | PIP4K2C | LZE24T | Human | Esophagus | ESCC | 1.48e-15 | 4.61e-01 | 0.0596 |
| 79837 | PIP4K2C | LZE21T | Human | Esophagus | ESCC | 6.49e-04 | 2.82e-01 | 0.0655 |
| 79837 | PIP4K2C | LZE6T | Human | Esophagus | ESCC | 9.76e-03 | 1.64e-01 | 0.0845 |
| 79837 | PIP4K2C | P1T-E | Human | Esophagus | ESCC | 2.82e-04 | 2.73e-01 | 0.0875 |
| 79837 | PIP4K2C | P2T-E | Human | Esophagus | ESCC | 5.50e-15 | 3.47e-01 | 0.1177 |
| 79837 | PIP4K2C | P4T-E | Human | Esophagus | ESCC | 1.27e-12 | 2.51e-01 | 0.1323 |
| 79837 | PIP4K2C | P5T-E | Human | Esophagus | ESCC | 3.90e-12 | 2.71e-01 | 0.1327 |
| 79837 | PIP4K2C | P8T-E | Human | Esophagus | ESCC | 1.97e-14 | 3.72e-01 | 0.0889 |
| 79837 | PIP4K2C | P9T-E | Human | Esophagus | ESCC | 1.27e-02 | 1.49e-01 | 0.1131 |
| 79837 | PIP4K2C | P10T-E | Human | Esophagus | ESCC | 5.10e-10 | 1.58e-01 | 0.116 |
| 79837 | PIP4K2C | P11T-E | Human | Esophagus | ESCC | 4.25e-05 | 4.25e-01 | 0.1426 |
| 79837 | PIP4K2C | P12T-E | Human | Esophagus | ESCC | 1.63e-17 | 3.19e-01 | 0.1122 |
| 79837 | PIP4K2C | P15T-E | Human | Esophagus | ESCC | 7.74e-18 | 4.03e-01 | 0.1149 |
| 79837 | PIP4K2C | P16T-E | Human | Esophagus | ESCC | 1.67e-10 | 1.93e-01 | 0.1153 |
| 79837 | PIP4K2C | P17T-E | Human | Esophagus | ESCC | 1.10e-10 | 4.94e-01 | 0.1278 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00464743 | Oral cavity | OSCC | glycerophospholipid biosynthetic process | 102/7305 | 211/18723 | 3.50e-03 | 1.48e-02 | 102 |
| GO:00066445 | Oral cavity | OSCC | phospholipid metabolic process | 175/7305 | 383/18723 | 4.21e-03 | 1.71e-02 | 175 |
| GO:00440903 | Oral cavity | OSCC | positive regulation of vacuole organization | 10/7305 | 13/18723 | 6.32e-03 | 2.35e-02 | 10 |
| GO:001623615 | Oral cavity | LP | macroautophagy | 135/4623 | 291/18723 | 4.71e-16 | 6.70e-14 | 135 |
| GO:001050615 | Oral cavity | LP | regulation of autophagy | 132/4623 | 317/18723 | 1.82e-11 | 1.28e-09 | 132 |
| GO:0009896110 | Oral cavity | LP | positive regulation of catabolic process | 187/4623 | 492/18723 | 2.30e-11 | 1.58e-09 | 187 |
| GO:0031331110 | Oral cavity | LP | positive regulation of cellular catabolic process | 163/4623 | 427/18723 | 3.03e-10 | 1.59e-08 | 163 |
| GO:000703313 | Oral cavity | LP | vacuole organization | 79/4623 | 180/18723 | 1.26e-08 | 4.74e-07 | 79 |
| GO:0051348110 | Oral cavity | LP | negative regulation of transferase activity | 106/4623 | 268/18723 | 4.60e-08 | 1.61e-06 | 106 |
| GO:001624113 | Oral cavity | LP | regulation of macroautophagy | 61/4623 | 141/18723 | 1.00e-06 | 2.50e-05 | 61 |
| GO:0010563110 | Oral cavity | LP | negative regulation of phosphorus metabolic process | 153/4623 | 442/18723 | 1.47e-06 | 3.53e-05 | 153 |
| GO:0045936110 | Oral cavity | LP | negative regulation of phosphate metabolic process | 152/4623 | 441/18723 | 2.10e-06 | 4.77e-05 | 152 |
| GO:190503711 | Oral cavity | LP | autophagosome organization | 47/4623 | 103/18723 | 2.88e-06 | 6.28e-05 | 47 |
| GO:000004512 | Oral cavity | LP | autophagosome assembly | 44/4623 | 99/18723 | 1.36e-05 | 2.40e-04 | 44 |
| GO:0042326110 | Oral cavity | LP | negative regulation of phosphorylation | 131/4623 | 385/18723 | 2.10e-05 | 3.46e-04 | 131 |
| GO:190211513 | Oral cavity | LP | regulation of organelle assembly | 71/4623 | 186/18723 | 2.94e-05 | 4.58e-04 | 71 |
| GO:0043434110 | Oral cavity | LP | response to peptide hormone | 138/4623 | 414/18723 | 4.00e-05 | 5.87e-04 | 138 |
| GO:003367318 | Oral cavity | LP | negative regulation of kinase activity | 86/4623 | 237/18723 | 4.19e-05 | 6.07e-04 | 86 |
| GO:190165317 | Oral cavity | LP | cellular response to peptide | 122/4623 | 359/18723 | 4.22e-05 | 6.10e-04 | 122 |
| GO:004408811 | Oral cavity | LP | regulation of vacuole organization | 23/4623 | 45/18723 | 1.19e-04 | 1.40e-03 | 23 |
| Page: 1 2 3 4 5 6 7 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0481028 | Esophagus | ESCC | Regulation of actin cytoskeleton | 133/4205 | 229/8465 | 5.94e-03 | 1.48e-02 | 7.56e-03 | 133 |
| hsa04810112 | Esophagus | ESCC | Regulation of actin cytoskeleton | 133/4205 | 229/8465 | 5.94e-03 | 1.48e-02 | 7.56e-03 | 133 |
| hsa0481041 | Liver | HCC | Regulation of actin cytoskeleton | 134/4020 | 229/8465 | 4.48e-04 | 1.94e-03 | 1.08e-03 | 134 |
| hsa0481051 | Liver | HCC | Regulation of actin cytoskeleton | 134/4020 | 229/8465 | 4.48e-04 | 1.94e-03 | 1.08e-03 | 134 |
| hsa0481026 | Oral cavity | OSCC | Regulation of actin cytoskeleton | 129/3704 | 229/8465 | 7.14e-05 | 2.74e-04 | 1.40e-04 | 129 |
| hsa04810111 | Oral cavity | OSCC | Regulation of actin cytoskeleton | 129/3704 | 229/8465 | 7.14e-05 | 2.74e-04 | 1.40e-04 | 129 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PIP4K2C | SNV | Missense_Mutation | c.777N>C | p.Lys259Asn | p.K259N | Q8TBX8 | protein_coding | deleterious(0.03) | possibly_damaging(0.838) | TCGA-A8-A094-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PIP4K2C | SNV | Missense_Mutation | c.955N>G | p.Pro319Ala | p.P319A | Q8TBX8 | protein_coding | tolerated(0.3) | benign(0.003) | TCGA-AC-A2B8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | chemo | PD | |
| PIP4K2C | SNV | Missense_Mutation | c.494N>G | p.Asn165Ser | p.N165S | Q8TBX8 | protein_coding | deleterious(0) | benign(0.005) | TCGA-B6-A0RP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| PIP4K2C | SNV | Missense_Mutation | c.192N>T | p.Gln64His | p.Q64H | Q8TBX8 | protein_coding | tolerated(1) | benign(0) | TCGA-E2-A15S-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| PIP4K2C | SNV | Missense_Mutation | novel | c.910N>A | p.Glu304Lys | p.E304K | Q8TBX8 | protein_coding | tolerated(0.33) | possibly_damaging(0.881) | TCGA-LD-A74U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | taxotere | SD |
| PIP4K2C | SNV | Missense_Mutation | novel | c.259C>T | p.His87Tyr | p.H87Y | Q8TBX8 | protein_coding | deleterious(0.02) | possibly_damaging(0.742) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| PIP4K2C | deletion | Frame_Shift_Del | c.333delN | p.Arg112ValfsTer63 | p.R112Vfs*63 | Q8TBX8 | protein_coding | TCGA-BH-A18T-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |||
| PIP4K2C | deletion | Frame_Shift_Del | novel | c.558delN | p.Met188CysfsTer15 | p.M188Cfs*15 | Q8TBX8 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| PIP4K2C | SNV | Missense_Mutation | novel | c.679N>A | p.Glu227Lys | p.E227K | Q8TBX8 | protein_coding | deleterious(0.04) | possibly_damaging(0.775) | TCGA-C5-A8YR-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| PIP4K2C | SNV | Missense_Mutation | rs140234878 | c.611N>A | p.Arg204His | p.R204H | Q8TBX8 | protein_coding | deleterious(0.03) | probably_damaging(0.996) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |